×
Biogen Revenue 2010-2024 | BIIB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Biogen revenue for the twelve months ending September 30, 2024 was
$9.608B
, a
3.86% decline
year-over-year.
Biogen annual revenue for 2023 was
$9.836B
, a
3.32% decline
from 2022.
Biogen annual revenue for 2022 was
$10.173B
, a
7.36% decline
from 2021.
Biogen annual revenue for 2021 was
$10.982B
, a
18.32% decline
from 2020.
View More
Biogen Revenue 2010-2024 | BIIB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Biogen annual revenue for 2023 was
$9.836B
, a
3.32% decline
from 2022.
Biogen annual revenue for 2022 was
$10.173B
, a
7.36% decline
from 2021.
Biogen annual revenue for 2021 was
$10.982B
, a
18.32% decline
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$127.1B
Gilead Sciences (GILD)
$114.2B
Bristol Myers Squibb (BMY)
$112.1B
CSL (CSLLY)
$91B
Regeneron Pharmaceuticals (REGN)
$89.7B
GSK (GSK)
$74.4B
Argenex SE (ARGX)
$35.2B
Alnylam Pharmaceuticals (ALNY)
$35.2B
BioNTech SE (BNTX)
$25.4B
Illumina (ILMN)
$24.2B
Moderna (MRNA)
$19.9B
BeiGene (BGNE)
$19.7B
Incyte (INCY)
$15.6B
Genmab (GMAB)
$14.8B
Insmed (INSM)
$13B
Vaxcyte (PCVX)
$13B
BioMarin Pharmaceutical (BMRN)
$12.6B
Sarepta Therapeutics (SRPT)
$12.2B
Bio-Techne Corp (TECH)
$12B
Exelixis (EXEL)
$10.1B
Exact Sciences (EXAS)
$10.1B
QIAGEN (QGEN)
$10B
Revolution Medicines (RVMD)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$8.2B
Ascendis Pharma (ASND)
$7.8B
Halozyme Therapeutics (HALO)
$7.7B